Identification of putative actionable alterations in clinically relevant genes in breast cancer.

ABSTRACT:

Background

Individualising treatment in breast cancer requires effective predictive biomarkers. While relatively few genomic aberrations are clinically relevant, there is a need for characterising patients across different subtypes to identify actionable alterations.

Methods

We identified genomic alterations in 49 potentially actionable genes for which drugs are available either clinically or via clinical trials. We explored the landscape of mutations and copy number alterations (CNAs) in actionable genes in seven breast cancer subtypes utilising The Cancer Genome Atlas. To dissect the genomic complexity, we analysed the patterns of co-occurrence and mutual exclusivity in actionable genes.

Results

We found that >30% of tumours harboured putative actionable events that

SUBMITTER: Kaur P 

PROVIDER: S-EPMC8548334 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature